MARKET

BLCM

BLCM

Bellicum Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.210
-0.100
-2.32%
Opening 14:20 01/22 EST
OPEN
4.220
PREV CLOSE
4.310
HIGH
4.300
LOW
4.200
VOLUME
154.74K
TURNOVER
--
52 WEEK HIGH
23.60
52 WEEK LOW
2.620
MARKET CAP
21.30M
P/E (TTM)
-0.3807
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Osteosarcoma Market Report | Major Factors Propelling Growth of Industry Size Valued By CAGR and Revenue Forecast Till 2025
Jan 21, 2021 (The Expresswire) -- "Final Report will add the analysis of the impact of COVID-19 on this industry." “Osteosarcoma Market” research report...
The Express Wire · 1d ago
Knee Bursitis Market Study of Revenue Details, Threats in the Target Market and Forecast By 2023
Jan 21, 2021 (Heraldkeepers) -- Increased pressure on the knees duet o rigorous activities is increasing the detection of knee bursitis cases. Moreover, the...
Heraldkeepers · 1d ago
34.5%+ growth for CAR-T Cell Therapy Market Size, Share to reach 8.92 billion USD by 2026
Market Insight Reports · 3d ago
Osteosarcoma Market Sales Statistics, Share Value, Key Players, Cost Analysis, COVID-19 Impact and Global Industry Insights By 2025
Jan 17, 2021 (Heraldkeepers) -- The occurrence of osteosarcoma is soaring among children and is more dominant among males. Osteosarcoma is accountable for...
Heraldkeepers · 5d ago
8-K: BELLICUM PHARMACEUTICALS, INC
(EDGAR Online via COMTEX) -- 0001358403false00013584032021-01-052021-01-050001358403dei:FormerAddressMember2021-01-052021-01-05 UNITED STATES SECURITIES AND...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 01/11 12:05
Zacks.com featured highlights include: Bellicum Pharmaceuticals, Prometic Life Sciences, Vaccinex, Meridian Bioscience and 360 DigiTech
Zacks.com · 01/07 13:19
Zacks.com featured highlights include: Bellicum Pharmaceuticals, Prometic Life Sciences, Vaccinex, Meridian Bioscience and 360 DigiTech
Zacks · 01/07 13:19
Bet on Rising P/E With These 5 Top-Ranked Stocks
Zacks · 01/06 13:43
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of BLCM. Analyze the recent business situations of Bellicum Pharms through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average BLCM stock price target is 4.500 with a high estimate of 4.500 and a low estimate of 4.500.
EPS
Institutional Holdings
Institutions: 99
Institutional Holdings: 9.62M
% Owned: 190.16%
Shares Outstanding: 5.06M
TypeInstitutionsShares
Increased
4
14.92K
New
9
2.41K
Decreased
9
32.09K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.74%
Pharmaceuticals & Medical Research
+0.79%
Key Executives
Chairman/Independent Director
James Brown
President/Chief Executive Officer/Director
Richard Fair
Senior Vice President
Aaron Foster
Controller
David Strauss
Independent Director
James Daly
Independent Director
Stephen Davis
Independent Director
Reid Huber
Independent Director
Judith Klimovsky
Independent Director
Jon Stonehouse
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About BLCM
Bellicum Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system. The Company is developing next-generation product candidates in the areas of cellular immunotherapy, including hematopoietic stem cell transplantation (HSCT), chimeric antigen receptors (CAR) T cells therapy and T-cell receptor (TCR) cell therapies. The Company's product candidates include BPX-501, BPX-601 and BPX-701. The Company's CID-based technologies include CaspaCIDe and GoCAR-T. It is evaluating BPX-501 in various Phase I/II clinical trials in adults and pediatric patients with leukemias, lymphomas and genetic blood diseases in the United States and Europe.
More

Webull offers kinds of Bellicum Pharmaceuticals Inc stock information, including NASDAQ:BLCM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BLCM stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BLCM stock methods without spending real money on the virtual paper trading platform.